Flag of the European Union EU Clinical Trials Register Help

Clinical trials for colitis ulcerosa

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    103 result(s) found for: colitis ulcerosa. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2009-010065-23 Sponsor Protocol Number: P05553 Start Date*: 2009-08-17
    Sponsor Name:Essex Pharma GmbH
    Full Title: Conventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05...
    Medical condition: Active Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10066678 Acute ulcerative colitis LLT
    14.1 10017947 - Gastrointestinal disorders 10033007 Other ulcerative colitis LLT
    14.1 10017947 - Gastrointestinal disorders 10045366 Ulcerative colitis, unspecified LLT
    14.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007928-18 Sponsor Protocol Number: Repha_1328 Start Date*: 2008-06-04
    Sponsor Name:REPHA GmbH
    Full Title: Evaluation of efficacy and safety of the herbal drug Myrrhinil-Intest vs. mesalazine in maintaining clinical remission of ulcerative colitis - a 12-month, multicenter, randomized, prospective, doub...
    Medical condition: ulcerative colitis patients in clinical remission
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004768-23 Sponsor Protocol Number: SIC002 Start Date*: 2013-06-12
    Sponsor Name:STELIC INSTITUTE & CO.
    Full Title: A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Efficacy in Patients with Ulcerative Colitis
    Medical condition: Ulcerative Colitis with active endoscopic lesion(s), ranging in severity from moderate to severe in endoscopic score not responding sufficiently to conventional treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017839-18 Sponsor Protocol Number: PG09-PUR 0210-002 Start Date*: 2010-05-14
    Sponsor Name:PurGenesis Techonologies Inc.
    Full Title: A 2-WEEK EXPLORATORY RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, DOSE-RANGING, PLACEBO-CONTROLLED SAFETY, TOLERABILITY, BIOMARKER AND EFFICACY CLINICAL STUDY OF PUR 0110 RECTAL ENEMA IN MILD-TO-MODER...
    Medical condition: Active mild-to-moderate distal ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003113-34 Sponsor Protocol Number: CLYS006X2202 Start Date*: 2020-02-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, multi-center, subject and investigator blinded, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of LYS006 in patients with mild to moderate ul...
    Medical condition: Mild to moderate ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) NO (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002350-36 Sponsor Protocol Number: GA39925 Start Date*: 2018-09-27
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO A...
    Medical condition: Ulcerative colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10033007 Other ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    20.0 100000004856 10075635 Acute hemorrhagic ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IE (Completed) HU (Completed) NL (Completed) BG (Completed) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002542-38 Sponsor Protocol Number: CAEB071A2210 Start Date*: 2007-11-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis.
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002013-19 Sponsor Protocol Number: ACT12688 Start Date*: 2013-07-19
    Sponsor Name:Sanofi aventis Recherche&Développement
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC).
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Completed) IT (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001830-32 Sponsor Protocol Number: SAT-25/UCA Start Date*: 2013-01-15
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine ver...
    Medical condition: Active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) LV (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001012-30 Sponsor Protocol Number: LTS12593 Start Date*: 2013-09-30
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) AT (Completed) BE (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004878-26 Sponsor Protocol Number: IM011-127 Start Date*: 2021-01-05
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis.
    Medical condition: Moderate to Severe Ulcerative Colitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003409-36 Sponsor Protocol Number: GA27927 Start Date*: 2011-11-14
    Sponsor Name:Genentech, Inc.
    Full Title: A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of rhuMAb Beta7 in Patients with Moderate to Severe Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001686-12 Sponsor Protocol Number: 20210210 Start Date*: 2023-02-17
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Moderate to Severe Active Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004576-57 Sponsor Protocol Number: BUX-4/UCA Start Date*: 2019-04-26
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Randomised, double-blind, double-dummy, active-controlled, phase III clinical trial on the efficacy and safety of an 8-week add-on treatment with budesonide 9 mg capsules vs. budesonide 6 mg capsul...
    Medical condition: Patients with active ulcerative colitis refractory to standard treatment with mesalazine
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) SK (Completed) LT (Prematurely Ended) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005635-14 Sponsor Protocol Number: BUX-3/UCA Start Date*: 2015-06-08
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative c...
    Medical condition: Patients with active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004997-32 Sponsor Protocol Number: GA40209 Start Date*: 2018-12-10
    Sponsor Name:Roche Farma, S.A por delegación de Genentech, Inc.
    Full Title: A PHASE II OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE
    Medical condition: Ulcerative Colitis (UC) or Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10033007 Other ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    20.0 100000004856 10075635 Acute hemorrhagic ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) IE (Prematurely Ended) DE (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000897-80 Sponsor Protocol Number: ABS4986g Start Date*: 2011-08-16
    Sponsor Name:Genentech, Inc.
    Full Title: PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF rhuMAb BETA7 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) GB (Prematurely Ended) ES (Prematurely Ended) DE (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005232-30 Sponsor Protocol Number: AMUC-2023 Start Date*: 2021-06-21
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects with Mild to Moderate Ulcerative Colitis (UC)
    Medical condition: Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) DE (Completed) CZ (Completed) BG (Completed) SK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004469-41 Sponsor Protocol Number: PN-943-03 Start Date*: 2020-05-11
    Sponsor Name:Protagonist Therapeutics, Inc
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects with Moderate to Severe Active Ulcerative C...
    Medical condition: Ulcerative colitis (US) is a chronic relapsing inflammatory bowel disease of the large intestine characterized by bloody diarrhoea, abdominal cramps and fatigue. UC is characterized by inflammation...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004565-15 Sponsor Protocol Number: FE 999907 CS003 Start Date*: 2005-04-06
    Sponsor Name:Ferring BV
    Full Title: Pentasa® Once Daily In Ulcerative colitis for Maintenance of remission: PODIUM An International multi-centre investigator blinded randomised controlled study of Pentasa ® Sachet comparing one gra...
    Medical condition: Ulcerative collitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    4.1 10009900 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) SE (Completed) CZ (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:21:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA